<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680143</url>
  </required_header>
  <id_info>
    <org_study_id>0304845</org_study_id>
    <nct_id>NCT04680143</nct_id>
  </id_info>
  <brief_title>Systemic Erythropoietin Injection in Patients Having Optic Atrophy</brief_title>
  <official_title>Systemic Erythropoietin Injection in Patients Having Optic Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this treatment trial is to study the effect of systemic erythropoietin in&#xD;
      patients having optic atrophy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this treatment trial is to study the effect of systemic erythropoietin in&#xD;
      patients having optic atrophy. The intervention is systemic erythropoietin injections (eprax&#xD;
      10000 IU subcutaneous twice daily for three days).&#xD;
&#xD;
      Follow up after one month and three months by recording visual acuity and electro&#xD;
      physiological studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Actual">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study included 10 patients diagnosed as post papilledemic optic atrophy that were attending Alexandria main university hospital. All patients underwent initially assessment of visual acuity, color vision, pupil reaction ,funduscopy and electrophysiological tests ( pattern visual evoked potential and pattern electroretinogram in both eyes to use data of the normal fellow eye as patients' internal control). Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days). Follow up after one month and three months by recording visual acuity and electro physiological studies.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>VIsual acuity assessed at the follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pattern visual evoked Potential .</measure>
    <time_frame>3 months</time_frame>
    <description>Pattern visual evoked Potential .in both eyes to use data of the normal fellow eye as patients' internal control</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pattern electroretinogram</measure>
    <time_frame>3 months</time_frame>
    <description>Pattern electroretinogram in both eyes to use data of the normal fellow eye as patients' internal control</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Optic Atrophy</condition>
  <arm_group>
    <arm_group_label>Systemic erythropoietin injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study included 10 patients diagnosed as post papilledemic optic atrophy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systemic erythropoietin injection</intervention_name>
    <description>Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).</description>
    <arm_group_label>Systemic erythropoietin injections</arm_group_label>
    <other_name>Eprax 10000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Post papilledemic optic atrophy patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refuse to give an informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mai ElBahwash, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alexandria Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Mohamed Fahmy Doheim</investigator_full_name>
    <investigator_title>Prinicipal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

